Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Statussort icon Initial Date
<a href="/venture-capital/all-companies/bg-medicine-inc">BG Medicine, Inc.</a> Developing and delivering diagnostic solutions to aid in the clinical management of heart failure and related disorders. Public 2000 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. Public 2007 View Profile
<a href="/venture-capital/all-companies/concert-pharmaceuticals-inc">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Public 2006 View Profile
<a href="/venture-capital/all-companies/acceleron-pharma-inc">Acceleron Pharma, Inc.</a> Discovering, developing and commercializing novel protein therapeutics for cancer and rare diseases. Public 2004 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Nanomedicine platform company developing Accurins, its novel targeted therapeutics. Public 2007 View Profile
<a href="/venture-capital/all-companies/eleven-biotherapeutics-inc">Eleven Biotherapeutics, Inc.</a> Discovering and developing protein therapeutics to treat diseases of the eye. Public 2008 View Profile
<a href="/venture-capital/all-companies/receptos-inc">Receptos, Inc.</a> Developing therapeutic candidates for the treatment of immune and metabolic diseases. Public 2009 View Profile
<a href="/venture-capital/all-companies/affinnova-inc">Affinnova, Inc.</a> Global marketing technology company that dramatically improves innovation and marketing success rates. Private 2000 View Profile
<a href="/venture-capital/all-companies/joule-unlimited-inc">Joule Unlimited, Inc.</a> Advancing a technology platform for Liquid Fuel from the Sun™. Private 2007 View Profile
<a href="/venture-capital/all-companies/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> Developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Private 2008 View Profile
<a href="/venture-capital/all-companies/seventh-sense-biosystems-inc">Seventh Sense Biosystems, Inc.</a> Developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. Private 2007 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Setting a new standard in clinical diagnostics powered by T2MR, the world’s first direct detection technology. Private 2006 View Profile
<a href="/venture-capital/all-companies/transmedics-inc">TransMedics, Inc.</a> Extending the life saving benefits of organ transplantation to patients suffering from end-stage organ failure. Private 2010 View Profile
<a href="/venture-capital/all-companies/avedro-inc">Avedro, Inc.</a> Advancing the science and technology of corneal crosslinking. Private 2009 View Profile
<a href="/venture-capital/all-companies/black-duck-software-inc">Black Duck Software, Inc.</a> Offering award-winning software and consulting. Private 2004 View Profile
<a href="/venture-capital/all-companies/quantum-designs">Quantum Designs</a> Commercializing breakthrough, innovative products in human nutrition. Private 2012 View Profile
<a href="/venture-capital/all-companies/celexion-llc">Celexion LLC</a> Developing powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. Private 2009 View Profile
<a href="/venture-capital/all-companies/permeon-biologics-inc">Permeon Biologics Inc.</a> Pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Private 2011 View Profile
<a href="/venture-capital/all-companies/taris-biomedical-inc">TARIS Biomedical, Inc.</a> Developing a pipeline of innovative treatments for bladder diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/novomer-inc">Novomer, Inc.</a> Commercializing a family of low-cost, high-performance, sustainable polymers and other chemicals. Private 2007 View Profile